The Markey Cancer Center (MCC) will utilize developmental funds, leveraged with institutional and philanthropic funds, to support pilot grants and strategic new faculty recruitments. Pilot grant funding ($125,000) from the CCSG will support collaborative and interdisciplinary cancer research focusing on MCC priority areas;funded projects will be carried out by interactions between MCC members in our four research programs and supported by our six shared resource facilities. Pilot funds will stimulate high return on investment research that makes a significant impact in the field of basic, clinical, population, or translational cancer research. New faculty recruitment priorities have been established based on the MCC Strategic Plan in consultation with Senior and Program Leaders and include recruitment of: 1) a senior level molecular epidemiologist in years 1-3 ($50,000 each year);and 2) a drug discovery scientist in years 4-5 ($50,000 each year).

Public Health Relevance

Developmental funds will allow the MCC to invest in those areas of cancer research that present the greatest opportunity, and are vital to the continued success of the MCC. The MCC requests Developmental Funds from the CCSG to fund pilot research projects and to recruit new faculty;both endeavors will support the goal of translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA177558-01
Application #
8740612
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-07-08
Project End
2018-06-30
Budget Start
2013-07-08
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$245,915
Indirect Cost
$81,972
Name
University of Kentucky
Department
Type
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Shi, Jian; Wang, Yifan; Zeng, Lei et al. (2014) Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 25:210-25
Tuna, Halide; Avdiushko, Rita G; Sindhava, Vishal J et al. (2014) Regulation of the mucosal phenotype in dendritic cells by PPAR?: role of tissue microenvironment. J Leukoc Biol 95:471-85
Huang, Yan; Hu, Yin; Liu, Jinze (2014) Piecing the puzzle together: a revisit to transcript reconstruction problem in RNA-seq. BMC Bioinformatics 15 Suppl 9:S3
Chen, Li; Voronovich, Zoya; Clark, Kenneth et al. (2014) Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 16:1478-83
Barone, Eugenio; Di Domenico, Fabio; Butterfield, D Allan (2014) Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol 88:605-16
Förster, Sarah; Welleford, Andrew S; Triplett, Judy C et al. (2014) Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochim Biophys Acta 1842:1333-9
Gilbert, Misty R; Liu, Yinxing; Neltner, Janna et al. (2014) Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol 127:221-33
Farr, Susan A; Ripley, Jessica L; Sultana, Rukhsana et al. (2014) Antisense oligonucleotide against GSK-3? in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 67:387-95
Cenini, Giovanna; Fiorini, Ada; Sultana, Rukhsana et al. (2014) An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radic Biol Med 76:89-95
Liu, Yinxing; Gilbert, Misty R; Kyprianou, Natasha et al. (2014) The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathol 128:723-32

Showing the most recent 10 out of 17 publications